ANK2 and catecholaminergic polymorphic ventricular tachycardia: CaMKII inhibition is a potential therapy in inherited diseases characterized by disordered intracellular Ca2+ handling such as RyR2-mediated catecholaminergic polymorphic ventricular tachycardia (CPVT) (145, 146), long QT syndrome (147, 148), Timothy syndrome with mutations in the L-type voltage-gated Ca2+ 1.2 channel (52), Barth syndrome (149), Duchenne muscular dystrophy (150), and ankyrin-B mutations (151).